The expert consensus pathway provides recommendations for the evaluation and management of adults with myocarditis and long COVID following COVID-19 infection.
A study shows that individuals in the post-acute phase of COVID-19 exhibited increased risks and 12-month burdens of incident CV diseases, compared to individuals with no evidence of SARA-CoV-2 infection.
A cross-sectional study showed subclinical signs of affection of the pulmonary, cardiac, coagulation and renal systems in mainly non-hospitalized individuals who had mild to moderate SARS-CoV-2 infection ~9 months ago.
Anticoagulation after discharge may be necessary for a short time in patients who were hospitalized due to COVID-19 and have a high thrombotic risk, according to prof. Verheugt.
The MICHELLE trial shows that extended post-discharge thromboprophylaxis with the NOAC rivaroxaban for 35 days improved clinical outcomes compared to no anticoagulation in patients with high risk of thromboembolism who were hospitalized due to COVID-19.
The Task Force for the management of COVID-19 of the ESC has published two documents that are aimed to provide guidance for the diagnosis and management of CVD during the COVID-19 pandemic.
AHA 2021 As part of the ACTIV-4a study, it was examined whether use of P2Y12 inhibitors (ticagrelor or clopidogrel) changed the number of organ support-free days in a period of 28 days in non-critically ill hospitalized patients with COVID-19.
AHA 2021 Rafael Diaz explains the rationale and shares the results of the PREPARE-IT-2-study, which investigated whether icosapent ethyl resulted in a reduction of clinical outcomes in patients with COVID-19.
AHA 2021 The PREPARE IT-2 trial enrolled non-hospitalized COVID-19 patients and showed that icosapent ethyl did not reduce COVID-19-related hospitalization or death compared to placebo after 28 days.
Is a therapeutic dose of heparin in COVID-19 patients more effective than standard dose heparin? Prof. ten Cate gives an update on the most recent findings.
In an open-label, multiplatform, randomized trial, therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin did not improve clinical outcomes compared to usual-care pharmacologic thromboprophylaxis in critically ill COVID-19 patients.
This study described the clinical features of 23 patients who after receiving the first dose of ChAdOx1 nCoV-19 vaccine developed atypical platelet factor 4 (PF4)-dependent thrombosis and/or thrombocytopenia that resembles heparin-induced thrombocytopenia.